ArticleStem cell research & therapy2025
Production of clinical grade patient iPSC-derived 3D retinal organoids containing transplantable photoreceptor cells.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Restorative and regenerative therapies for vision loss.Eye (London, England) · 2026Review
- Photoreceptor replacement: a disease-agnostic approach for the treatment of advanced retinal degeneration.Eye (London, England) · 2026Review
- Stem cell-based therapies for neuroretinal degeneration: current landscape and future perspectives.Stem cells translational medicine · 2026Review
- Cell therapy for age-related macular degeneration.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Review
- Intriguing roles of Müller glia: a special emphasis on the development and pathology of Müller glia cells in the retina.International ophthalmology · 2026Review
- Generation of xenobiotic free retinofugal assembloids.Frontiers in cell and developmental biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundNeurodegenerative conditions that affect the retina are currently the leading cause of incurable blindness in the developed world. Although gene and drug therapies are being developed to slow disease progression in some cases, restorative cell replacement approaches are needed for patients with significant vision impairment due to retinal degeneration. While a variety of different cell types have been evaluated in the context of retinal cell replacement, induced pluripotent stem cells (iPSCs), which can be generated and delivered as an autologous therapeutic, are in many ways the most attractive donor cell source currently available. Like embryonic stem cells, iPSCs must be differentiated into the target therapeutic cell type prior to transplantation. For instance, for patients with retinitis pigmentosa who have primary photoreceptor cell disease, photoreceptor cell derivation and enrichment are required prior to transplantation. Although other effective retinal differentiation protocols exist, they are often not fully compatible with clinical manufacturing.
methodsPatient-derived iPSCs were generated via Sendai viral vector mediated reprogramming of dermal fibroblasts. Retinal organoids were generated using a stepwise 3D differentiation protocol testing different current good manufacturing practice (cGMP) compliant reagents and oxygen tension in a cGMP compliant Biospherix cell culture isolator. Organoids were dissociated with papain and photoreceptor precursor cells were transplanted into immune suppressed Pde6b-null rats. Human donor cell survival, cellular identity, and synaptic integration were assessed at 3- and 30-days post-injection.
resultsWe developed of a xeno-free 3D retinal differentiation protocol based on the most robust adherent/non-adherent 3D differentiation strategies published to date. In addition, we demonstrate that while iPSC reprogramming efficiency is enhanced under reduced oxygen tension (i.e., 5%), efficient embryoid body and subsequent retinal organoid production require standard oxygen levels (i.e., 20%). Finally, we show that photoreceptor precursor cells obtained from 3D retinal organoids derived using the developed protocol under cGMP survive in the subretinal space of dystrophic Pde6b-null rats for 30 days post-transplantation and form new synaptic connections with host bipolar neurons. Importantly, synaptic connectivity between transplanted photoreceptor cells and host bipolar neurons appeared to have a positive trophic effect.
conclusionsIn this study, we report development of a xeno-free, cGMP compliant iPSC-3D retinal differentiation protocol for production of transplantable photoreceptor precursor cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.